KR102210848B1 - 3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법 - Google Patents

3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법 Download PDF

Info

Publication number
KR102210848B1
KR102210848B1 KR1020157006421A KR20157006421A KR102210848B1 KR 102210848 B1 KR102210848 B1 KR 102210848B1 KR 1020157006421 A KR1020157006421 A KR 1020157006421A KR 20157006421 A KR20157006421 A KR 20157006421A KR 102210848 B1 KR102210848 B1 KR 102210848B1
Authority
KR
South Korea
Prior art keywords
cinnamyl
piperazinyl
delete delete
formilipamycin
rifamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157006421A
Other languages
English (en)
Korean (ko)
Other versions
KR20150042275A (ko
Inventor
키릴 아세노브 니노브
벨리취카 일리에바 아포스톨로바-디모바
에브티미아 이바노바 스테파노바
로센 크루모브 코이트체브
루먀나 게오르귀에바 콘스탄티노바
Original Assignee
아디팜 에아드
푸둘로브, 보쥐다르 류베노브
푸둘로브, 리이보미르 보쥐다로브
키릴 아세노브 니노브
벨리취카 일리에바 아포스톨로바-디모바
에브티미아 이바노바 스테파노바
로센 크루모브 코이트체브
디트체브 컨설팅 오오드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아디팜 에아드, 푸둘로브, 보쥐다르 류베노브, 푸둘로브, 리이보미르 보쥐다로브, 키릴 아세노브 니노브, 벨리취카 일리에바 아포스톨로바-디모바, 에브티미아 이바노바 스테파노바, 로센 크루모브 코이트체브, 디트체브 컨설팅 오오드 filed Critical 아디팜 에아드
Publication of KR20150042275A publication Critical patent/KR20150042275A/ko
Application granted granted Critical
Publication of KR102210848B1 publication Critical patent/KR102210848B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
KR1020157006421A 2012-08-13 2013-08-09 3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법 Expired - Fee Related KR102210848B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BG11128812 2012-08-13
BG111288 2012-08-13
PCT/BG2013/000041 WO2014026254A1 (en) 2012-08-13 2013-08-09 Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation

Publications (2)

Publication Number Publication Date
KR20150042275A KR20150042275A (ko) 2015-04-20
KR102210848B1 true KR102210848B1 (ko) 2021-02-02

Family

ID=50101135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157006421A Expired - Fee Related KR102210848B1 (ko) 2012-08-13 2013-08-09 3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법

Country Status (18)

Country Link
US (2) US9682997B2 (https=)
EP (1) EP2882435B8 (https=)
JP (2) JP6400580B2 (https=)
KR (1) KR102210848B1 (https=)
CN (2) CN104736152B (https=)
BR (1) BR112015002945B1 (https=)
CA (1) CA2881958C (https=)
EA (1) EA029363B1 (https=)
ES (1) ES2876004T3 (https=)
HK (1) HK1248691A1 (https=)
HU (1) HUE054955T2 (https=)
IN (1) IN2015DN02009A (https=)
MX (1) MX380259B (https=)
PL (1) PL2882435T3 (https=)
PT (1) PT2882435T (https=)
UA (1) UA120030C2 (https=)
WO (1) WO2014026254A1 (https=)
ZA (1) ZA201501268B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386622B (es) * 2017-06-26 2025-03-19 Biofer Spa Derivados de pirido-imidazo rifamicina como agente antibacteriano
TWI731295B (zh) * 2019-01-24 2021-06-21 宏碁股份有限公司 顯示裝置以及控制顯示裝置的方法
CN119243181B (zh) * 2024-10-14 2025-10-10 河北欣港药业有限公司 一种微尺度下由利福霉素sv连续流电化学合成利福霉素s的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476036B1 (en) 1998-11-04 2002-11-05 Roumiana Gueorguieva Konstantinova Sodium salt of 3-(4-cinnamyl-1-piperazinyl)-imino-methyl rifamycin SV

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478563A (en) 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
GR64108B (en) 1977-04-15 1980-01-24 Dso Pharmachim Method for the preparation of azomethine-derivatives of rifamycin s.v
US4179439A (en) * 1977-07-01 1979-12-18 Intreprinderea De Antibiotice Iasi Rifamycins and method for their preparation
US4193020A (en) 1978-05-22 1980-03-11 Sperry Rand Corporation Phase lock control system with trajectory correction
JPS5738742A (en) * 1980-08-21 1982-03-03 Kawasaki Kasei Chem Ltd Preparation of 1,4-dihydroanthraquinone
JPS5695190A (en) * 1980-09-17 1981-08-01 Intorepurinderea De Anteibiote Manufacture of rifamycin derivative
IT1201963B (it) * 1983-03-24 1989-02-02 Prodotti Antibiotici Spa Derivati delle rifamicine e procedimento per la loro preparazione
JPS6143132A (ja) * 1984-08-06 1986-03-01 Takeda Chem Ind Ltd キノン誘導体，その製造法およびそれを含んでなる医薬組成物
MC1819A1 (fr) * 1985-10-18 1988-03-18 Ciba Geigy Ag Composes 4-benzyl-piperazinyl substitues
IT1202424B (it) * 1987-01-26 1989-02-09 Prodotti Antibiotici Spa Sali di un derivato rifamicinico
EP0284552A1 (de) * 1987-03-06 1988-09-28 Ciba-Geigy Ag 4-Benzyl-piperazinyl-Hydrazone
BG48618A1 (en) 1988-02-23 1991-04-15 Nauchen Inst Promishlena Mikro Method for preparing riphampycin
JPH02215716A (ja) * 1989-02-08 1990-08-28 Farmitalia Carlo Erba Spa ３―（ｎ―ピペリジノメチル―アジノ）メチルリファマイシンｓを活性成分として含有する薬剤組成物
US5095108A (en) * 1990-08-28 1992-03-10 Technologichen Kombinat Za Promishlena Microbiologia Non-solvated crystalline form "A" of 3-(4-cynnamyl-1-piperazinyl)iminomethylrifamycine SV and a method of its production
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10038101A1 (de) * 2000-08-04 2002-02-14 Degussa Verfahren zur Herstellung von 2-(4-Methyl-3-pentenyl)-anthrachinon
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1781670A1 (en) * 2004-07-22 2007-05-09 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476036B1 (en) 1998-11-04 2002-11-05 Roumiana Gueorguieva Konstantinova Sodium salt of 3-(4-cinnamyl-1-piperazinyl)-imino-methyl rifamycin SV

Also Published As

Publication number Publication date
US9981985B2 (en) 2018-05-29
CA2881958C (en) 2019-08-27
MX2015001963A (es) 2015-06-04
BR112015002945B1 (pt) 2021-08-31
BR112015002945A8 (pt) 2018-01-16
US20170283433A1 (en) 2017-10-05
EP2882435A4 (en) 2017-05-03
CN104736152B (zh) 2018-01-23
CA2881958A1 (en) 2014-02-20
US20150368263A1 (en) 2015-12-24
PT2882435T (pt) 2021-06-18
US9682997B2 (en) 2017-06-20
EA029363B1 (ru) 2018-03-30
UA120030C2 (uk) 2019-09-25
KR20150042275A (ko) 2015-04-20
JP6400580B2 (ja) 2018-10-03
ES2876004T3 (es) 2021-11-11
PL2882435T3 (pl) 2021-10-04
IN2015DN02009A (https=) 2015-08-14
HK1248691A1 (zh) 2018-10-19
JP2018199718A (ja) 2018-12-20
JP2015528823A (ja) 2015-10-01
HUE054955T2 (hu) 2021-10-28
CN107840854A (zh) 2018-03-27
JP6694029B2 (ja) 2020-05-13
ZA201501268B (en) 2016-01-27
CN104736152A (zh) 2015-06-24
EP2882435A1 (en) 2015-06-17
WO2014026254A1 (en) 2014-02-20
EA201590278A1 (ru) 2015-07-30
EP2882435B8 (en) 2024-01-03
HK1206980A1 (en) 2016-01-22
MX380259B (es) 2025-03-12
BR112015002945A2 (pt) 2017-12-05
EP2882435B1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
BG60755B2 (bg) Мометазонфуроат монохидрат, метод за получаването му и фармацевтичен състав
AU2014336747B2 (en) Crystal form of (r)-praziquantel and preparation method and application thereof
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
DE60210598T2 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
JP6694029B2 (ja) ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法
EA019689B1 (ru) Бензолсульфонат 2-[[[2-[(гидроксиацетил)амино]-4-пиридинил]метил]тио]-n-[4-(трифторметокси)фенил]-3-пиридинкарбоксамида, его кристаллы, его полиморфы и способы их получения
WO2003000681A1 (en) Antibacterial having quinolinecarboxamide skeleton
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
JP2008174551A (ja) ラベプラゾールナトリウムの結晶形態
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
CZ217694A3 (en) 3/2 hydrate and anhydrate of 7-/(7-(s)-amino-5-azaspiro/2.4/heptan-5-yl/-8-chloro-6-fluoro-1-/(1r,2s) 2-fluorocyclopropyl/-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, processes of selective production of 3/2 hydrate, crystals thereof and antibacterial agents based thereon
HK1206980B (en) Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation
US12180242B2 (en) Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof
CA3116783C (en) Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof
CN107141253A (zh) 一种阿立哌唑倍半水合物化合物
KR100989389B1 (ko) 새로운 결정형을 갖는 지프라시돈 염산염 및 이의 제조방법
KR20100125124A (ko) 피타바스타틴 헤미칼슘염의 신규한 결정형 및 그의 제조방법
DE2718976A1 (de) Neue 6-(m-aminophenyl)-2,3,5,6-tetrahydroimidazo eckige klammer auf 2,1-b eckige klammer zu thiazol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
CN106699669A (zh) 一种左旋吗啉硝唑晶型及其制备方法和药用组合物的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250128

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250128